The next frontier in managing obesity and T2D: The role of novel combinations for touchENDOCRINOLOGY

touchEXPERT OPINIONS for touchENDOCRINOLOGY Listen to three experts discuss the rationale behind glucagon-like peptide-1 (GLP-1)-based combination therapies and review the latest clinical evidence for these novel combinations. The expert faculty will provide their insights on what these combination treatments may mean for the future management of obesity with or without type 2 diabetes (T2D). The experts Dr Sue Pedersen, University of Calgary, Calgary, Canada Prof. Carel le Roux, University College Dublin, Dublin, Ireland Dr Donna Ryan, Pennington Biomedical Research Center, Baton Rouge, LA, USA This touchPODCAST is for healthcare professionals outside of the USA and UK. This activity is funded by an independent medical education grant from Novo Nordisk A/S. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.  For further information visit our website:  www.touchENDOCRINOLOGY.com